1
506 PATENTABSTRACTS The present invention is concerned with a mono- clonal antibody capable of preferentially recognizing arteriosclerotic lesions and prepared from a hybridoma obtained by fusing myeloma cells and cells capable of producing antibodies against arteriosclerotic lesions, such as spleen cells, peripheral lymphocyte of thymus and peripheral vascular cells, the antibody can be to use as an agent for detecting the presence of ar- teriosclerotic lesions and for treating ar- teriosclerosis. 5110802 OLIGONUCLEOTIDE PHOSPHONATES AND METHOD OF INHIBITING A HUMAN IMMUNODEFICIENCY VIRUS IN VITRO UTILIZING SAID OLIGONUCLEOTIDE PHOSPHONATES Edouard M Cantin, John A Zaia, R Bruce Wal- lace, John J Rossi assigned to City of Hope A method of inhibiting human immunodefi- ciency virus (HIV) comprising administering a therapeutically effective amount of an antiviral agent to attack the first splice aceeptor site of the tat III gene of HIV. 5110908 HAEMOPHILUS INFLUENZAE PEPTIDES AND PROTEINS Robert A Deich, Gar Ztotnick, Bruce Green as- signed to Praxis Biologics lnc Peptides and proteins related to an epitope com- prising an outer membrane protein of Haemophilus influenzae are described. The pep- tides and proteins can be prepared by methods including novel and improved methods of puiification from H. influenzae cultures, and by recombinant DNA and chemical synthetic tech- niques. Additionally, recombinant vectors con- taining nucleotide sequences encoding PBOMP- l and PBOMP-2 related peptides and proteins are also described. Recombinant vectors include plasmid DNA and viral DNA such as human viruses, animal viruses, insect viruses and bac- teriophages that direct the expression of the PBOMP-! and PBOMP-2 related peptides and proteins in appropriate host cells. The peptides, proteins and viruses both live and inactivated are used as immunogens in vaccine formulations to protect against H. influenzae infections. The peptides and proteins are also used as reagents in immunoassays as well as to prepare immuno- globulins for passive immunization. Use of the nucleotide sequences encoding the PBOMP related peptides and proteins in hybridization assays is also described. 5110910 VIRUCIDAL EUGLOBULIN PRECIPITATION Grace C Tsar assigned to Miles lnc A source for antibodies (both IgG and IgM types) is put into an aqueous solution which in- cludes a virucidal agent under conditions suffic- ient to assure substantially compIete dissolution of both the antibodies and the virucidal agent and virus inactivation. Then the pH, con- ductivity and antibody concentration of the solution are then changed to obtain conditions sufficient to assure the precipitation of substan- tially all antibodies while maintaining substan- tially all of the virucidal agent in the supernatant solution. In preferred embodiments, using a TNBP/TWEEN virucidal agent, the original solution conductivity ranges from about 0.03 to 0.20 M MHO/CM, the pH ranges from about 4.75 to 4.85, and the protein concentration, when measured at A280, ranges from a reading of ab- out 5 to 40. In the second precipitation step, the pH is changed to a range of about 6.0 to 7.5 and the conductivity is changed to a range of about 0.05 to 6.70 M MHO/CM to achieve an IgM pre- cipitation ranging from about 30 to 80~ by weight total protein. 5110911 HUMAN TUMOR-ASSOCIATED THOMSEN-FRIEDENREICH ANTIGEN Joh Samuel, B Michael Longenecker, Edmon- ton, Canada assigned to Biomira Inc Human tumor associated Thomsen- Friedenreich (TF) antigen is purified from adenocarcinoma conditioned media, adenocar- cinoma cell detergent extracts or plural effusion fluid by affinity chromatography using an in- solubilized TF-specific monoclonal antibody, MAb 49H.8. The TF antigen is a glycoprotein characterized by a non-cryptic Gal beta(1 right arrow3) GalNAc epitope, a molecular weight in

5110802 Oligonucleotide phosphonates and method of inhibiting a human immunodeficiency virus in vitro utilizing said oligonucleotide phosphonates

Embed Size (px)

Citation preview

Page 1: 5110802 Oligonucleotide phosphonates and method of inhibiting a human immunodeficiency virus in vitro utilizing said oligonucleotide phosphonates

506 PATENT ABSTRACTS

The present invention is concerned with a mono- clonal antibody capable of preferentially recognizing arteriosclerotic lesions and prepared from a hybridoma obtained by fusing myeloma cells and cells capable of producing antibodies against arteriosclerotic lesions, such as spleen cells, peripheral lymphocyte of thymus and peripheral vascular cells, the antibody can be to use as an agent for detecting the presence of ar- teriosclerotic lesions and for treating ar- teriosclerosis.

5110802

O L I G O N U C L E O T I D E P H O S P H O N A T E S A N D M E T H O D

O F I N H I B I T I N G A H U M A N I M M U N O D E F I C I E N C Y V I R U S I N

V I T R O U T I L I Z I N G S A I D O L I G O N U C L E O T I D E

P H O S P H O N A T E S

Edouard M Cantin, John A Zaia, R Bruce Wal- lace, John J Rossi assigned to City of Hope

A method of inhibiting human immunodefi- ciency virus (HIV) comprising administering a therapeutically effective amount of an antiviral agent to attack the first splice aceeptor site of the tat III gene of HIV.

5110908

H A E M O P H I L U S I N F L U E N Z A E P E P T I D E S A N D P R O T E I N S

Robert A Deich, Gar Ztotnick, Bruce Green as- signed to Praxis Biologics lnc

Peptides and proteins related to an epitope com- prising an outer membrane protein of Haemophilus influenzae are described. The pep- tides and proteins can be prepared by methods including novel and improved methods of puiification from H. influenzae cultures, and by recombinant DNA and chemical synthetic tech- niques. Additionally, recombinant vectors con- taining nucleotide sequences encoding PBOMP- l and PBOMP-2 related peptides and proteins are also described. Recombinant vectors include plasmid DNA and viral DNA such as human viruses, animal viruses, insect viruses and bac- teriophages that direct the expression of the PBOMP-! and PBOMP-2 related peptides and proteins in appropriate host cells. The peptides, proteins and viruses both live and inactivated are used as immunogens in vaccine formulations to

protect against H. influenzae infections. The peptides and proteins are also used as reagents in immunoassays as well as to prepare immuno- globulins for passive immunization. Use of the nucleotide sequences encoding the PBOMP related peptides and proteins in hybridization assays is also described.

5110910

V I R U C I D A L E U G L O B U L I N P R E C I P I T A T I O N

Grace C Tsar assigned to Miles lnc

A source for antibodies (both IgG and IgM types) is put into an aqueous solution which in- cludes a virucidal agent under conditions suffic- ient to assure substantially compIete dissolution of both the antibodies and the virucidal agent and virus inactivation. Then the pH, con- ductivity and antibody concentration of the solution are then changed to obtain conditions sufficient to assure the precipitation of substan- tially all antibodies while maintaining substan- tially all of the virucidal agent in the supernatant solution. In preferred embodiments, using a TNBP/TWEEN virucidal agent, the original solution conductivity ranges from about 0.03 to 0.20 M MHO/CM, the pH ranges from about 4.75 to 4.85, and the protein concentration, when measured at A280, ranges from a reading of ab- out 5 to 40. In the second precipitation step, the pH is changed to a range of about 6.0 to 7.5 and the conductivity is changed to a range of about 0.05 to 6.70 M MHO/CM to achieve an IgM pre- cipitation ranging from about 30 to 80~ by weight total protein.

5110911

H U M A N T U M O R - A S S O C I A T E D T H O M S E N - F R I E D E N R E I C H

A N T I G E N

Joh Samuel, B Michael Longenecker, Edmon- ton, Canada assigned to Biomira Inc

Human tumor associated Thomsen- Friedenreich (TF) antigen is purified from adenocarcinoma conditioned media, adenocar- cinoma cell detergent extracts or plural effusion fluid by affinity chromatography using an in- solubilized TF-specific monoclonal antibody, MAb 49H.8. The TF antigen is a glycoprotein characterized by a non-cryptic Gal beta(1 right arrow3) GalNAc epitope, a molecular weight in